Recurrent Glioblastoma

Oncology
7
Pipeline Programs
7
Companies
5
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
150%
Monoclonal Antibody
150%
+ 5 programs with unclassified modality

On Market (1)

Approved therapies currently available

Bristol Myers Squibb
OPDIVOApproved
nivolumab
Bristol Myers Squibb
injection2015

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
1
NivolumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT02017717Completed529Est. Jun 2024
Lassen Therapeutics
Lassen TherapeuticsCA - San Diego
1 program
1
BIBF1120Phase 2
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BIBF1120Phase 21 trial
Active Trials
NCT01251484Completed25Est. Aug 2012
DS
Daiichi SankyoChina - Shanghai
1 program
1
PLX3397Phase 21 trial
Active Trials
NCT01349036Terminated38Est. Nov 2013
Cue Biopharma
Cue BiopharmaBOSTON, MA
1 program
1
CUE-102Phase 11 trial
Active Trials
NCT06917885Recruiting18Est. Jan 2028
One Biosciences
One BiosciencesFrance - Paris
1 program
1
Dendritic Cell Tumor Cell Lysate VaccinePhase 1Vaccine
Alpha Tau Medical
Alpha Tau MedicalJERUSALEM, Israel
1 program
Device :DaRT seedsN/A1 trial
Active Trials
NCT06910306Recruiting10Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Bristol Myers SquibbNivolumab
Daiichi SankyoPLX3397
Boehringer IngelheimBIBF1120
Cue BiopharmaCUE-102
Alpha Tau MedicalDevice :DaRT seeds

Clinical Trials (5)

Total enrollment: 620 patients across 5 trials

NCT02017717Bristol Myers SquibbNivolumab

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

Start: Feb 2014Est. completion: Jun 2024529 patients
Phase 3Completed
NCT01349036Daiichi SankyoPLX3397

A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

Start: Dec 2011Est. completion: Nov 201338 patients
Phase 2Terminated
NCT01251484Boehringer IngelheimBIBF1120

BIBF 1120 in Recurrent Glioblastoma Multiforme

Start: Jan 2011Est. completion: Aug 201225 patients
Phase 2Completed
NCT06917885Cue BiopharmaCUE-102

CUE-102 in Recurrent Glioblastoma

Start: Jul 2025Est. completion: Jan 202818 patients
Phase 1Recruiting
NCT06910306Alpha Tau MedicalDevice :DaRT seeds

A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

Start: Oct 2025Est. completion: Dec 202610 patients
N/ARecruiting

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 620 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)